Avalo Therapeutics Inc (AVTX) Unusual Options Activity Today

Checking AVTX unusual options activity helps you spot when traders are making outsized bets on Avalo Therapeutics Inc before the broader market catches on. Avalo Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor AVTX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching AVTX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking AVTX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and AVTX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis.

Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Catalysts rarely arrive without a footprint, and AVTX unusual options activity is often where that footprint shows up first. Our scanner tracks Avalo Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at AVTX unusual options volume on the call side or chasing put sweeps, Avalo Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.